Dianthus Therapeutics Inc. (DNTH) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Dianthus Therapeutics Inc. (NASDAQ: DNTH) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $82.25 (-0.16% 1D, market cap $4.61B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, DNTH ranks #478 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DNTH carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -30.7%. By comparison, TVTX (Travere Therapeutics Inc.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -13.0%, cap $4.75B) and PTCT (PTC Therapeutics Inc.) posts a C grade (63/100 RQD, P/E 7.9x, ROIC 85.0%, cap $5.01B). Among the 5-stock peer group, PTCT leads on earnings multiple (7.9x) while PTCT leads on capital efficiency (85.0% ROIC).
Per DNTH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001690585), Dianthus Therapeutics Inc. generated $2.0M in revenue (-67.3% YoY), -$162.3M in net income, and -$129.2M in free cash flow against $530.9M in total assets and $16.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Macro rate sensitivity & RSI-14 (46.8) create a -15 pt regime headwind
While DNTH currently carries a cautious 39/100 (D-) rating due to Macro Regime Fit (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($91.05) and Max Pain ($86.36) forces dealer call-delta covering toward $123.77.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Dianthus Therapeutics Inc. (DNTH) slipped -0.16% to $82.25, trading at 58% of its 52-week range ($32.28 – $117.88). Stretched risk/reward at current multiples (-31% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Dianthus Therapeutics Inc. (DNTH) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Dianthus Therapeutics Inc. (DNTH) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Dianthus Therapeutics Inc. (DNTH) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Dianthus Therapeutics Inc. (DNTH) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Dianthus Therapeutics Inc. (DNTH) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Dianthus Therapeutics Inc. (DNTH) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Dianthus Therapeutics Inc. (DNTH) market action, institutional positioning, and fundamental catalysts.
Kalkine India report covering Dianthus Therapeutics Inc. (DNTH) market action, institutional positioning, and fundamental catalysts.
Regeneron (REGN) delivered earnings and revenue surprises of +24.81% and +12.43%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on DNTH today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for DNTH. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Dianthus Therapeutics Inc. (DNTH) ranks #478 by composite RQD confidence (39/100, grade D-) and #169 by equity capitalization ($4.61B). Within this direct 5-issuer industry benchmark cohort, PTCT leads on earnings valuation at 7.9x trailing P/E, while PTCT leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. PTCT currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with DNTH at 39/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DNTH
ACTIVE
Dianthus Therapeutics Inc. | D- | 39/100 | — | — | -30.7% | -0.16% | $4.61B | Benchmark Subject |
| TVTX Travere Therapeutics Inc. | D+ | 52/100 | — | 96.0% | -13.0% | -2.24% | $4.75B | /tvtx-vs-dnth → |
| PTCT PTC Therapeutics Inc. | C | 63/100 | 7.9x | — | 85.0% | +1.52% | $5.01B | /ptct-vs-dnth → |
| ERAS Erasca Inc. | E | 33/100 | — | — | -35.0% | -2.09% | $5.02B | /eras-vs-dnth → |
| EWTX Edgewise Therapeutics Inc. | D- | 41/100 | — | — | -31.9% | -2.03% | $4.22B | /ewtx-vs-dnth → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Dianthus Therapeutics Inc. (DNTH) reported GAAP revenue of $2.0M (-67.3% vs. FY2024 revenue of $6.2M , and -28.0% cumulative change since FY2023) , GAAP net income of -$162.3M, operating cash flow of -$129.1M, and free cash flow of -$129.2M (-64.6% YoY). On the balance sheet, DNTH closed FY2025 with $530.9M in total assets against $16.9M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $2.0M | -$162.3M | -$129.1M | -$129.2M | $530.9M | $16.9M |
| FY2024 (FY) | 2024-12-31 | $6.2M | -$85.0M | -$78.2M | -$78.5M | $374.0M | $9.7M |
| FY2023 (FY) | 2023-12-31 | $2.8M | -$43.5M | -$36.9M | -$37.0M | $2.54B | $595.3M |
As of 2026-11-03, Dianthus Therapeutics Inc. (NASDAQ: DNTH) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $82.25 (-0.16% 1D, market cap $4.61B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, DNTH ranks #478 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DNTH carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -30.7%. By comparison, TVTX (Travere Therapeutics Inc.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -13.0%, cap $4.75B) and PTCT (PTC Therapeutics Inc.) posts a C grade (63/100 RQD, P/E 7.9x, ROIC 85.0%, cap $5.01B). Among the 5-stock peer group, PTCT leads on earnings multiple (7.9x) while PTCT leads on capital efficiency (85.0% ROIC).
Per DNTH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001690585), Dianthus Therapeutics Inc. generated $2.0M in revenue (-67.3% YoY), -$162.3M in net income, and -$129.2M in free cash flow against $530.9M in total assets and $16.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
DNTH last traded at $82.25 (-0.16% on volume of 837,834 shares), positioning the stock -9.67% below its 50-day simple moving average ($91.05) and -3.91% below its 200-day simple moving average ($85.60). Across its 52-week range of $32.28 to $117.88, DNTH sits at the 58.4% percentile with a 14-day RSI of 46.8 (NEUTRAL RANGE) and an implied next-earnings move of ±9.4% ($74.52 to $89.98).
Dianthus Therapeutics Inc. (DNTH) earns a live Roarable RQD composite score of 39/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $82.25 (-0.16% 1D, market capitalization $4.61B).
Dianthus Therapeutics Inc. (DNTH) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations. The company's products, customers, and revenue model are not described in the source data. Reported revenue was $2.0M in FY 2025, $6.2M in FY 2024, and $2.8M in FY 2023. Market capitalization is $4.6B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Dianthus Therapeutics Inc. (DNTH) reported $2.0M in annual revenue (up from $6.2M in FY2024, -67.3% YoY) and -$162.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.8M revenue, -$43.5M net income) through FY2025, DNTH scaled operating cash flow to -$129.1M and free cash flow to -$129.2M, backed by $530.9M in total assets against $16.9M in total debt.
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), DNTH carries a macro regime beta of 1.08 and gross margin of —.
Real-time company headlines, analyst actions, and sector developments for Dianthus Therapeutics Inc. (DNTH) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Dianthus Therapeutics Inc. (DNTH) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Dianthus Therapeutics Inc. (DNTH) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Dianthus Therapeutics Inc. (DNTH) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Dianthus Therapeutics Inc. (DNTH) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Dianthus Therapeutics Inc. (DNTH) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Dianthus Therapeutics Inc. (DNTH) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Dianthus Therapeutics Inc. (DNTH) market action, institutional positioning, and fundamental catalysts.
Kalkine India report covering Dianthus Therapeutics Inc. (DNTH) market action, institutional positioning, and fundamental catalysts.
Picked up a starter position in DNTH in my $100K Virtual Cash book at $82.38. Low leverage (Debt/Equity 0.03) and a forward P/E of 20 give the balance sheet and forward earnings expectations some support despite heavy losses.. Trading inside a $32.42–$117.88 52-week range with -2.79% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.
@MultipleCompression Fair point on 20.0x forward P/E, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
Careful chasing DNTH at $82.38. ROIC of -30.7%, FCF of -$129.2M in FY 2025, and negative operating margin of -60% show the cash engine is consuming capital rather than generating it.. Gross margin is 0.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $64.26 on multiple compression.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).